EMA Withdrawn: Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.) (formoterol fumarate dihydrate;glycopyrronium;beclometasone dipropionate) — Chiesi Farmaceutici S.p.A.

View source ↗

Summary

EMA has withdrawn the COPD inhaler Riarify, a fixed-dose triple therapy containing formoterol fumarate dihydrate, glycopyrronium, and beclometasone dipropionate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Riarify (formoterol fumarate dihydrate; glycopyrronium; beclometasone dipropionate)

Snippet

Status: Withdrawn. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Chiesi Farmaceutici S.p.A.. Decision date: 04/11/2024